RA
HELP

Royce & Associates’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Royce & Associates’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
232,078
+77,028
+50% +$385K 0.01% 642
2026
Q1 		$744K Buy
+155,050
New +$1M 0.01% 676

Other funds holding HELP

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

Royce & Associates's HELP Position: Q2 2026 in Review

Royce & Associates increased its Helus Pharma Inc. Common Stock (HELP) stake by 50% in Q2 2026, buying an estimated $385K and bringing the position to 232,078 shares worth $1.53M. The position accounts for 0.01% of the portfolio, ranked #642.

Royce & Associates first reported a position in HELP in Q1 2026 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold HELP as of Q2 2026.

  • Royce & Associates held 232,078 shares of Helus Pharma Inc. Common Stock worth $1.53M as of Q2 2026.
  • Royce & Associates bought 77,028 Helus Pharma Inc. Common Stock shares in Q2 2026, an estimated $385K.
  • Helus Pharma Inc. Common Stock made up 0.01% of Royce & Associates's portfolio in Q2 2026, its #642 holding.
  • Royce & Associates first reported a position in Helus Pharma Inc. Common Stock in Q1 2026 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.